Competitive Technologies, Inc., today reported retained royalties of $133, 000 from its laser diode technology used in DVD-RAM drives for PCs and other
optical storage devices for the first six months of fiscal 1999. This represents a 22% increase over the prior year comparable period. This follows CTT’s announcement on January 26,
1999 of the grant of a non-exclusive license to Mitsubishi Electric Corporation. Mitsubishi is the third corporation to take a license to this technology. CTT has targeted other electronics
companies worldwide and continues an aggressive licensing campaign.

Frank McPike, President of CTT stated “DVD-RAM sales are just beginning to take off and we are positioning our Company and our client, the University of Illinois, to benefit as
consumers begin to add DVD-RAM to their PC’s. We expect to see our royalties continue to grow as sales of DVD-RAM drives increase and as we add to our list of licensees. Our
$133,000 royalty payment for the first half of fiscal 1999 is revenue of about $0.02 a share for us and we would expect that number to be substantially higher in the second half.”

Market growth for DVD-RAM drives, worldwide is expected to grow from 200,000 units in 1998 to 9 million units in the year 2000. Drives for DVD-RAM have begun making their
appearance at retail outlets for as little as $500. These drives can record and re-record, or rewrite data onto DVD drives.

CTT’s technology provides the ability to increase the performance and durability of high-powered lasers used in high power optical storage devices, such as DVD drives, and thus a
solution to the common problem of low reliability during long-term operation.

Mr. McPike went on to say that CTT “represents three additional technologies that have the potential to provide solutions in billion dollar markets: a unique low processing power
Encryption technology with Internet and e-commerce security applications; plasma display panel energy recovery and sustain circuitry necessary in 42 inch and larger flat panel TV’s; and
the Homocysteine assay which is in the market as a marker for cardiovascular disease, which some studies correlating elevated levels of Homocysteine with additional diseases such as
Alzheimer’s, chronic fatigue syndrome and rheumatoid arthritis.”